US President Donald Trump has announced a phased tariff structure targeting imported generic pharmaceuticals, giving foreign drugmakers a two-year window to relocate manufacturing to the United States or face duties of up to 200%.
The policy aims to force pharmaceutical companies to build domestic production plants in America. The announcement carries significant economic implications for India, which serves as the largest foreign supplier of generic medicines to the US market.
Phased Tariff Timeline
Taking to Truth Social, Trump outlined a three-tier rollout schedule beginning in mid-2026:
| Phase | Timeline | Applicable Tariff Rate |
| Phase 1 | August 1, 2026 – July 31, 2028 | 0% (Duty-free grace period) |
| Phase 2 | August 1, 2028 – July 31, 2029 | 100% tariff |
| Phase 3 | August 1, 2029 onwards | 200% tariff |
“This is done in order to RESHORE generic pharmaceutical production into America, with a penalty to those companies that decide not to build plants and equipment within the stated period of time,” Trump posted. He noted that existing rules governing patented, branded, or innovative drugs will remain unchanged.
High Stakes for India’s “Pharmacy of the World”
India produces approximately 40% of all generic drugs by volume consumed in the United States. Key details surrounding the trade exposure include:
-
Export Volume: In FY 2024–25, India exported $9.7 billion in pharmaceuticals to the US, accounting for 38% of its total global pharma exports ($25.8 billion).
-
Critical Supply Lines: Indian manufacturers supply the majority of essential US generic prescriptions, including treatments for hypertension, diabetes, depression, cancer, and infectious diseases. In categories like oral contraceptives, two Indian firms—Glenmark and Lupin—accounted for nearly 65% of all US prescriptions in 2024.
-
Trade Agreement Nuances: India and the US previously signed a trade framework in February stipulating negotiated outcomes regarding generics, leaving the long-term enforcement mechanism between the two nations under active review.
